LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
Keizman
Daniel
D
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Eisenberger
Mario A
MA
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone